3,064 results match your criteria Prostate Cancer - Metastatic and Advanced Disease


Minimally invasive, 'en-bloc' seminal vesicle excision for locally advanced rectal adenocarcinoma: surgical technique and short-term outcomes.

ANZ J Surg 2022 Jun 28. Epub 2022 Jun 28.

Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India.

Background: Isolated seminal vesicle invasion is a rare occurrence in patients with locally advanced rectal cancers. This study describes the surgical technique and the perioperative outcomes of minimally invasive 'en-bloc' seminal vesicle excision, preserving the bladder and the prostate.

Methods: A retrospective review of 23 consecutive patients who underwent minimally invasive, en-bloc resection of seminal vesicles for locally advanced, non-metastatic rectal adenocarcinoma between May 2016 and November 2021. Read More

View Article and Full-Text PDF

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review.

Front Oncol 2022 8;12:932637. Epub 2022 Jun 8.

Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.

Globally, prostate cancer is one of the most common malignancies affecting men. With the advent of advanced molecular imaging, an increasing number of men are found to have oligometastatic disease (OD) either at primary diagnosis or at the time of biochemical failure. No strict definition exists for OD, with historical and ongoing studies utilizing diverse criteria. Read More

View Article and Full-Text PDF

Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours.

EClinicalMedicine 2022 Jul 27;49:101430. Epub 2022 May 27.

Department of Internal Medicine, Division of Hematology/Oncology, Mayo Clinic Cancer Center, Phoenix, AZ, USA.

Background: PT-112, the first pyrophosphate-platinum conjugate, causes immunogenic cell death in experimental models, leading to recruitment of tumour-infiltrating lymphocytes. PT-112 also associates with bone (osteotropism), likely driven by its pyrophosphate moiety. This is the first-in-human study of PT-112 monotherapy, exploring its safety and efficacy in a patient population where standard of care therapies were exhausted and novel treatment options are needed. Read More

View Article and Full-Text PDF

Systemic Ablation of Impairs Metastatic Colonization and Improves Insulin Sensitivity in TRAMP Mice: Evidence for Cancer Cell-Extrinsic CAMKK2 Functions in Prostate Cancer.

Cells 2022 06 10;11(12). Epub 2022 Jun 10.

Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.

Despite early studies linking calcium-calmodulin protein kinase kinase 2 (CAMKK2) to prostate cancer cell migration and invasion, the role of CAMKK2 in metastasis in vivo remains unclear. Moreover, while CAMKK2 is known to regulate systemic metabolism, whether CAMKK2's effects on whole-body metabolism would impact prostate cancer progression and/or related comorbidities is not known. Here, we demonstrate that germline ablation of slows, but does not stop, primary prostate tumorigenesis in the TRansgenic Adenocarcinoma Mouse Prostate (TRAMP) genetic mouse model. Read More

View Article and Full-Text PDF

PARP Inhibitors: A New Horizon for Patients with Prostate Cancer.

Biomedicines 2022 Jun 15;10(6). Epub 2022 Jun 15.

Urology and Nephrology Department, University Hospital Virgen del Rocío, 41013 Seville, Spain.

The introduction of PARP inhibitors (PARPi) in prostate cancer is a milestone and provides a pathway to hope in fighting this disease. It is the first time that drugs, based on the concept of synthetic lethality, have been approved for prostate cancer. In addition, it is also the first time that genetic mutation tests have been included in the therapeutic algorithm of this disease, representing a significant step forward for precision and personalized treatment of prostate cancer. Read More

View Article and Full-Text PDF

Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer.

Tomography 2022 Jun 3;8(3):1477-1484. Epub 2022 Jun 3.

PET Imaging Centre, University Hospital of North Norway, 9019 Tromsø, Norway.

Background: 18F-fluciclovine is a positron emission tomography (PET) radiotracer approved for the detection of prostate cancer recurrence. No effect of androgen deprivation therapy (ADT) on its performance has been established.

Purpose: To study the impact of concurrent ADT on disease detection with 18F-fluciclovine PET in patients with prostate cancer. Read More

View Article and Full-Text PDF

An appraisal of genetic testing for prostate cancer susceptibility.

NPJ Precis Oncol 2022 Jun 22;6(1):43. Epub 2022 Jun 22.

Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.

Most criteria for genetic testing for prostate cancer susceptibility require a prior diagnosis of prostate cancer, in particular cases with metastatic disease are selected. Advances in the field are expected to improve outcomes through tailored treatments for men with advanced prostate cancer with germline pathogenic variants, although these are not currently offered in the curative setting. A better understanding of the value of genetic testing for prostate cancer susceptibility in screening, for early detection and prevention is necessary. Read More

View Article and Full-Text PDF

Acute and late toxicity of prostate-only or pelvic SBRT in prostate cancer: A Comparative Study.

Int J Radiat Oncol Biol Phys 2022 Jun 17. Epub 2022 Jun 17.

Department of Medical Physics, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India.

Objective: To compare the urinary and gastrointestinal toxicity with or without the inclusion of pelvic nodal regions in patients treated with extreme hypofractionated stereotactic radiotherapy (SBRT) for prostate cancer.

Methods: Patients treated with definitive SBRT for non-metastatic adenocarcinoma prostate were identified from prospectively maintained institutional database, and details of radiotherapy volume, dose, acute and late adverse effects were analyzed. Symptoms of acute (within 90 days of completing SBRT) and late gastrointestinal and urinary toxicities were graded using CTCAE version 5. Read More

View Article and Full-Text PDF

A Systematic Review of the Treatment Outcomes among Prostate Cancer Patients in Africa.

Cancer Invest 2022 Jun 24:1-11. Epub 2022 Jun 24.

Department of Pharmacy, Faculty of Health Sciences, University of Nairobi, Nairobi, Kenya.

Prostate cancer (PCa) is associated with a significant public health burden in Africa. This systematic review aimed to assess treatment outcomes among PCa patients in Africa. A systematic search of the literature was conducted from 1 December 2021 to 31 March 2022 to identify relevant published studies. Read More

View Article and Full-Text PDF

Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.

J Transl Med 2022 Jun 15;20(1):271. Epub 2022 Jun 15.

Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.

After the success of immunotherapy in the treatment of advanced metastatic cancer, further evaluation in earlier settings, including high-risk, surgically-resectable disease is underway. Potential benefits of a neoadjuvant immunotherapeutic approach include presurgical tumor shrinkage, reduced surgical morbidity, early eradication of micrometastases and prevention of distant disease, and greater antigen-specific T cell response. For some cancers, pathologic response has been established as a surrogate measure for long-term outcomes, therefore offering the ability for early and objective assessment of treatment efficacy and the potential to inform and personalize adjuvant treatment clinical decision-making. Read More

View Article and Full-Text PDF

Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate.

Can Urol Assoc J 2022 Jun 9. Epub 2022 Jun 9.

Department of Medical Oncology, BC Cancer - Victoria, Victoria, BC, Canada.

Introduction: Unresectable and metastatic small cell carcinoma of the prostate (SCPC) is a rare and aggressive disease that is under-represented in clinical trials. We carried out a retrospective chart review of metastatic or unresectable SCPC patients at British Columbia (BC) Cancer centers, studying diagnosis and treatment patterns.

Methods: Drug dispensing records from the six BC Cancer centers were obtained from 2002- 2017. Read More

View Article and Full-Text PDF

Radiopharmaceutical for detecting PSMA - positive metastatic colon cancer: Matched-pair comparison of 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI.

Nucl Med Rev Cent East Eur 2022 Jun 14. Epub 2022 Jun 14.

Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul,Turkey.

Prostate-specific membrane antigen (PSMA) - based radiopharmaceuticals are promising for the evaluation of PSMA-positive non-prostate cancers. In this case study, 18F-BF3-Cy3-ACUPA and 68Ga-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) were compared in a patient with metastatic colon cancer. Both 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI showed biopsy-proven metastatic left external iliac adenopathy, highlighting the feasibility of PSMA uptake in PET/MRI of metastatic nodal disease from colon cancer. Read More

View Article and Full-Text PDF

The importance of personalized medicine in urological cancers.

J Diabetes Metab Disord 2022 Jun 29;21(1):841-852. Epub 2021 Jun 29.

Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

A better understanding of key regulatory pathways involved in cancers has led to the development of molecularly targeted therapies. Molecular profiling based on genomics, proteomics, and metabolomics in tumors provides clinicians with the necessary information to maintain a personalized therapeutic regimen according to the patient's needs. for example, androgen deprivation therapy (ADT) for advanced prostate cancer is one of the earliest forms of targeted therapy and has remained a choice of treatment by physicians. Read More

View Article and Full-Text PDF

Recent advances in the treatment of advanced prostate cancer: maximizing existing therapies while searching for novel solutions.

Authors:
Theodore Gourdin

Curr Opin Oncol 2022 05;34(3):228-233

Division of Hematology Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.

Purpose Of Review: Present highlights from recent research examining treatment of advanced prostate cancer.

Recent Findings: Data are emerging that combining androgen deprivation, docetaxel, and additional androgen-receptor-targeted therapies in treatment naïve metastatic prostate cancer may be an effective strategy to improve outcomes. Genomically targeted therapies and radiopharmaceuticals continue to be evaluated in the treatment of advanced castration-resistant prostate cancer. Read More

View Article and Full-Text PDF

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.

NAR Cancer 2022 Jun 27;4(2):zcac016. Epub 2022 May 27.

Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.

Sequencing of cell-free DNA (cfDNA) in cancer patients' plasma offers a minimally-invasive solution to detect tumor cell genomic alterations to aid real-time clinical decision-making. The reliability of copy number detection decreases at lower cfDNA tumor fractions, limiting utility at earlier stages of the disease. To test a novel strategy for detection of allelic imbalance, we developed a prostate cancer bespoke assay, PCF_SELECT, that includes an innovative sequencing panel covering ∼25 000 high minor allele frequency SNPs and tailored analytical solutions to enable allele-informed evaluation. Read More

View Article and Full-Text PDF

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.

PLoS One 2022 2;17(6):e0269192. Epub 2022 Jun 2.

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.

Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy. Our objective was to determine the value for money to the English National Health Service (NHS) of adding AAP to SOC. We used a decision analytic model to evaluate cost-effectiveness of providing AAP in the English NHS. Read More

View Article and Full-Text PDF

Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives.

Med Sci (Basel) 2022 04 28;10(2). Epub 2022 Apr 28.

Urology Department, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Catholic University of the Sacred Heart, 00168 Rome, Italy.

Prostate cancer therapy for locally advanced and metastatic diseases includes androgen deprivation therapy (ADT). Second-generation antiandrogens have a role in castration-resistant prostate cancer. Nevertheless, some patients do not respond to this therapy, and eventually all the patients became resistant. Read More

View Article and Full-Text PDF

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide.

Oncologist 2022 May 30. Epub 2022 May 30.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Background: Despite the clinical efficacy of enzalutamide monotherapy in patients with advanced prostate cancer, therapeutic resistance and disease progression are inevitable. We proposed a study to evaluate NLG207, a nanoparticle-drug conjugate (NDC) of the potent topoisomerase I inhibitor camptothecin, in combination with enzalutamide, in patients with metastatic castration-resistant prostate cancer (mCRPC) following progression on enzalutamide.

Methods: This was a single-arm, optimal two-stage, phase II study to evaluate the efficacy of NLG207 in combination with enzalutamide in patients with mCRPC who received prior enzalutamide. Read More

View Article and Full-Text PDF

Diagnostic Age, Age at Death and Stage Migration in Men Dying with or from Prostate Cancer in Denmark.

Diagnostics (Basel) 2022 May 19;12(5). Epub 2022 May 19.

Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital, Rigshospitalet, 2200 Copenhagen, Denmark.

The impact of changes in diagnostic activity and treatment options on prostate cancer epidemiology remains a subject of debate. Newly published long-term survival outcomes may not represent contemporary patients and new perspectives are in demand. All men dying in Denmark with prostate cancer diagnosis during a 10-year period were analyzed to address the stage migration of and time lived with prostate cancer diagnosis. Read More

View Article and Full-Text PDF

Male Breast Metastasis: A Case of Treatment-Emergent Neuroendocrine Prostate Cancer.

Cureus 2022 Apr 19;14(4):e24283. Epub 2022 Apr 19.

Internal Medicine, Hospital Prof. Doutor Fernando Fonseca, Amadora, PRT.

Treatment-emergent transformed neuroendocrine prostate cancer (NEPC) is a highly aggressive type of prostate cancer that may arise from typical adenocarcinoma of the prostate, which is associated with rapidly progressive disease involving visceral sites and refractoriness to hormonal therapy. We present the case of a 74-year old male with a known history of stable prostate adenocarcinoma treated with transurethral prostate resection, local radiotherapy (RT), and androgen deprivation therapy (ADT) in 2020 who presented to the emergency room with complaints of shoulder and anterior chest pain, dyspnoea, and fatigue. Upon examination, a solid, adherent breast mass and infra-clavicular adenopathy were palpable. Read More

View Article and Full-Text PDF

Molecular mechanisms underlying the development of neuroendocrine prostate cancer.

Semin Cancer Biol 2022 May 18. Epub 2022 May 18.

Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University, Palo Alto, CA, USA. Electronic address:

Prostate cancer is the most common non-cutaneous cancer and the second leading cause of cancer-associated deaths among men in the United States. Androgen deprivation therapy (ADT) is the standard of care for advanced prostate cancer. While patients with advanced prostate cancer initially respond to ADT, the disease frequently progresses to a lethal metastatic form, defined as castration-resistant prostate cancer (CRPC). Read More

View Article and Full-Text PDF

Advances in PSMA theranostics.

Transl Oncol 2022 Aug 18;22:101450. Epub 2022 May 18.

Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, 413 East 69th Street, Room BB-1604, New York, NY 10021, USA; Weill Cornell Medicine, Citigroup Biomedical Imaging Center, New York, NY 10021, USA. Electronic address:

The validation of prostate specific membrane antigen (PSMA) as a molecular target in metastatic castration-resistant prostate cancer has stimulated the development of multiple classes of theranostic ligands that specifically target PSMA. Theranostic ligands are used to image disease or selectively deliver cytotoxic radioactivity to cells expressing PSMA according to the radioisotope conjugated to the ligand. PSMA theranostics is a rapidly advancing field that is now integrating into clinical management of prostate cancer patients. Read More

View Article and Full-Text PDF

Nationwide Industry-Led Community Exercise Program for Men With Locally Advanced, Relapsed, or Metastatic Prostate Cancer on Androgen-Deprivation Therapy.

JCO Oncol Pract 2022 May 18:OP2100745. Epub 2022 May 18.

Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia.

Purpose: Androgen-deprivation therapy in patients with prostate cancer (PCa) is associated with considerable side effects and secondary comorbidities such as overweight/obesity and cardiovascular disease. The aim of this study was to investigate the effectiveness of an industry-led, treatment-integrated, community-based exercise program on outcomes of body weight, cardiovascular health, and physical function.

Patients And Methods: PCa patients with locally advanced, relapsed, or metastatic disease receiving leuprorelin acetate were enrolled across multiple sites in Australia and assigned supervised group exercise undertaken weekly or biweekly (ie, 16 exercise sessions in total) for 10-18 weeks, consisting of aerobic and resistance training performed at moderate-to-vigorous intensity. Read More

View Article and Full-Text PDF

Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance.

Cancer Drug Resist 2022 19;5(1):93-101. Epub 2022 Jan 19.

Department of Biochemistry and Molecular Biology, LSU Health Sciences Center, Shreveport, LA 71103, USA.

Standard treatment for advanced Prostate Cancer (PCa) consists of androgen deprivation therapy (ADT), but ultimately fails, resulting in the incurable phase of the disease: metastatic castration-resistant prostate cancer (mCRPC). Targeting PCa cells before their progression to mCRPC would greatly improve the outcome, if strategies could be devised selectively targeting androgen receptor (AR)-dependent and/or independent compensatory pathways which promote mCRPC development. Combination therapy by targeting the DNA damage response (DDR) along with ADT has been limited by general toxicity, and a goal of clinical trials is how to target the DDR more specifically. Read More

View Article and Full-Text PDF
January 2022

Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.

Cancer Treat Res 2022 ;183:201-223

Division of Urology, Taichung Veterans General Hospital, 1650, Taiwan Boulevard Sect. 4, Taichung, Taiwan, 40705.

Immunotherapy, the 5th pillar of cancer care after surgery, radiotherapy, cytotoxic chemotherapy, and precision therapy (molecular targeted therapy), is revolutionizing the standard of care in certain patients with genitourinary malignancies. As modest clinical benefits of IL-2 for metastatic renal cell carcinoma and Bacillus Calmette-Guerin therapy for early-stage bladder cancers in the past years, immune checkpoint inhibitors therapies demonstrate meaningful survival benefit and durable clinical response in renal cell carcinoma, urothelial carcinoma, and some prostate cancer. Despite best efforts, the benefits are limited to a minority of unselected patients due to the complexities of biomarker development. Read More

View Article and Full-Text PDF

Outcome of 177Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters: A Single-Center Experience.

Clin Nucl Med 2022 May 11. Epub 2022 May 11.

From the Department of Nuclear Medicine, Istanbul Faculty of Medicine.

Purpose: This study was set out to analyze the efficacy and safety of 177Lu-PSMA-617 (LuPSMA) treatment in metastatic castration-resistant prostate cancer (mCRPC) patients.

Patients And Methods: Progressive mCRPC patients who received at least 1 cycle of LuPSMA therapy were evaluated retrospectively. Demographic, clinic, and histopathological data were documented. Read More

View Article and Full-Text PDF

A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.

Saudi J Biol Sci 2022 Apr 15;29(4):2072-2084. Epub 2022 Jan 15.

Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, 1988, Najran 61441, Saudi Arabia.

Genitourinary cancers comprise of a heterogenous group of cancers of which renal cell carcinoma, urothelial bladder carcinoma, and prostate adenocarcinoma are the most commonly encountered subtypes. A lot of research is ongoing using various strategies for exploration of novel biomarkers for genitourinary cancers. These biomarkers would not reduce the need for invasive diagnostic techniques but also could be used for early and accurate diagnosis to improve the clinical management required for the disease. Read More

View Article and Full-Text PDF

Association of blood pressure with prostate cancer risk by disease severity, and prostate cancer death: a pooled cohort study.

Cancer Epidemiol Biomarkers Prev 2022 May 5. Epub 2022 May 5.

Lund University, Lund, Sweden.

Background: The association of blood pressure (BP) with prostate cancer risk after accounting for asymptomatic prostate-specific antigen (PSA) testing, and with prostate cancer death, is unclear.

Methods: We investigated BP, measured at a mean age of 38 years amongst 430,472 men from five Swedish cohorts, in association with incident prostate cancer (n=32,720) and prostate cancer death (n=6718). Hazard ratios (HRs) were calculated from multivariable Cox regression models. Read More

View Article and Full-Text PDF

Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?

Prostate Int 2022 Mar 9;10(1):68-74. Epub 2021 Mar 9.

Department of Urology, Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, South Korea.

The expansion of the indication to use androgen deprivation therapy (ADT) to treat patients with advanced or metastatic prostate cancer has dramatically increased over the recent decades, resulting in the progress of patients' survival. However, chronic health implications can become more apparent as the number of long-term cancer survivors is expected to be increased along with the adverse effect of ADT. In particular, interest in investigating ADT, especially luteinizing hormone-releasing hormone (LHRH) agonist association with cognitive dysfunction has been growing. Read More

View Article and Full-Text PDF

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.

Clin Epigenetics 2022 05 4;14(1):60. Epub 2022 May 4.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

The androgen receptor (AR) is a prostate master transcription factor. It binds to genetic enhancers, where it regulates gene activity and plays a fundamental role in prostate pathophysiology. Previous work has demonstrated that AR-DNA binding is systematically and consistently reprogrammed during prostate tumorigenesis and disease progression. Read More

View Article and Full-Text PDF